Welcome to our dedicated page for Oscar Health news (Ticker: OSCR), a resource for investors and traders seeking the latest updates and insights on Oscar Health stock.
Oscar Health, Inc. (NYSE: OSCR) generates a steady flow of news as a healthcare technology company that combines Individual & Family health insurance plans with a full stack technology platform. Company press releases frequently highlight new market entries, specialized plan designs, and technology-driven member support tools, making OSCR news relevant for investors and observers of the health insurance and digital health sectors.
Much of Oscar’s recent news focuses on the expansion of its affordable, tech-powered health plans across U.S. regions. The company has announced new offerings for individuals, families, and businesses in areas such as Southern Florida, the Tampa Bay area, Orlando and Central Florida, Charlotte and surrounding North Carolina markets, Columbus in Ohio, the Dallas/Fort Worth region in Texas, and multiple counties in Arizona. These announcements detail the availability of Bronze, Silver, Gold, and Redesigned Gold plans, as well as specialized options like HelloMeno menopause plans, condition-focused plans for chronic conditions, Guided Care HMO products, and Spanish-first diabetes plans.
Oscar’s news also covers partnerships and employer-focused initiatives. For example, the Hy-Vee Health with Oscar plan in the Des Moines business community showcases an employer-funded individual market arrangement using an ICHRA structure, combining health coverage, concierge-style care, and lifestyle rewards. In addition, many releases emphasize the role of Oswell, Oscar’s personal health AI agent, and Oscar Care Guides in providing on-demand support and navigation for members.
Investors following OSCR news will also find updates on financial performance and capital structure in the company’s earnings announcements and related Form 8-K filings. These communications include quarterly results, membership metrics, guidance updates, and details on convertible note offerings and exchange agreements. For ongoing insight into how Oscar is expanding its footprint, refining its technology platform, and managing its financial profile, this news feed provides a centralized view of the company’s public disclosures.
Oscar Health (NYSE: OSCR) will release its Q3 2025 financial results before the market opens on Thursday, November 6, 2025. Management will discuss results on a conference call starting at 8:00 AM ET.
Investors can join by phone at 1.855.761.5600 (Conference ID: 7768132) or listen via webcast. The webcast will be archived on the company's investor relations site for 90 days after November 6, 2025.
Oscar Health (NYSE:OSCR) has successfully priced an upsized offering of $355 million in convertible senior subordinated notes due 2030, with a 2.25% interest rate. The offering, increased from the initially announced $350 million, includes an option for purchasers to buy an additional $55 million in notes.
The notes will convert at an initial rate of 40.2946 shares per $1,000 principal amount, representing a conversion price of $24.82 per share - a 32.5% premium over the last closing price. To mitigate dilution, Oscar entered into capped call transactions with a cap price of $37.46 per share.
Net proceeds of approximately $342.5 million will support general corporate purposes, including AI initiatives, healthcare experience enhancement, and potential premium tax credit extensions. The company will also terminate its existing revolving credit facility upon the offering's closing.
Oscar Health (NYSE:OSCR) has announced plans to offer $350 million in convertible senior subordinated notes due 2030, with an additional option for purchasers to buy up to $52.5 million in notes. The offering aims to support general corporate purposes, including AI initiatives, healthcare cost reduction, and enhanced consumer experiences.
The notes will be convertible to cash, class A common stock, or a combination thereof. To mitigate potential dilution, Oscar will enter into capped call transactions. The company plans to terminate its existing revolving credit facility upon the offering's closing. The notes will be redeemable after September 6, 2028, if Oscar's stock price exceeds 130% of the conversion price for a specified period.
Oscar Health (NYSE:OSCR) and Hy-Vee have announced a strategic partnership to launch Hy-Vee Health with Oscar, an innovative employer healthcare benefit program. The initiative will debut in Des Moines, Iowa, targeting approximately 400,000 employees through the individual marketplace starting November 1, 2025.
The program offers significant cost savings, with businesses potentially saving 20% to 30% and employees saving $500 to $1,000 annually. Key benefits include $0 care at Hy-Vee Health Exemplar Care clinics, access to MercyOne specialists, affordable prescriptions at Hy-Vee pharmacies, dedicated Oscar Care Guides, and Hy-Vee rewards for grocery savings.
Oscar Health (NYSE:OSCR) reported its Q2 2025 financial results, showing significant revenue growth but facing profitability challenges. Total revenue reached $2.9 billion, up from $2.2 billion in Q2 2024, driven by increased membership to 2.02 million members.
The company reported a net loss of $228.4 million ($0.89 per share) compared to a net income of $56.2 million in Q2 2024. The medical loss ratio increased to 91.1% from 79.0%, while the SG&A expense ratio improved to 18.7% from 19.6%. Management expects market stabilization in 2026 and anticipates a return to profitability, viewing the individual market as having long-term growth potential.
Oscar Health (NYSE:OSCR) released preliminary Q2 2025 results and revised its 2025 guidance downward. The company expects a Q2 2025 operating loss of $230 million and a net loss of $228 million. The revision follows analysis of 2025 Marketplace data showing higher-than-expected ACA Marketplace risk scores.
For full year 2025, Oscar now projects total revenue of $12.0-12.2 billion, a medical loss ratio of 86.0-87.0%, and an SG&A expense ratio of 17.1-17.6%. The company anticipates a loss from operations between $300 million and $200 million. In response, Oscar plans to resubmit 2026 rate filings for approximately 98% of current membership to reflect higher market risk scores.
Oscar Health (NYSE: OSCR), a healthcare technology company, has scheduled its first quarter 2025 financial results release and earnings conference call. The company will announce Q1 2025 results before market opening on Wednesday, May 7, 2025, followed by a management conference call at 8:00 AM ET.
Investors can access the call via phone at 1.855.761.5600 (Conference ID: 7768132) or through webcast. The call recording will be available on Oscar's investor relations website (ir.hioscar.com) for 90 days after the event.
Ataraxis AI has secured a $20.4 million Series A financing round led by AIX Ventures, with participation from notable investors including Peter Thiel and former Oscar Health (NYSE: OSCR) CEO Mario Schlosser. The company's AI foundation model, Kestrel, powers their first product Ataraxis Breast, which has shown to be 30% more accurate than current breast cancer care standards in clinical validation.
The platform is set to launch for clinical use across the United States later this year. The funding will support expanding treatment selection capabilities within and beyond breast cancer. The company has formed a Clinical Advisory Board featuring oncology leaders from top health systems, including experts from Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center, and NYU.
Oscar Health (NYSE: OSCR) reported its strongest financial performance in company history for 2024, achieving profitability for the first time. Total revenue reached $9.2 billion, up 56.5% year-over-year, driven by membership growth during Open Enrollment and Special Enrollment Period additions.
Key financial metrics include a Medical Loss Ratio of 81.7% (10 bps increase YoY), SG&A Expense Ratio of 19.1% (520 bps improvement YoY), and net income of $25.4 million ($0.10 per diluted share). Adjusted EBITDA was $199.2 million, improving by $244.5 million YoY.
For 2025, Oscar projects revenue between $11.2-11.3 billion, Medical Loss Ratio of 80.7-81.7%, and SG&A Expense Ratio of 17.6-18.1%. The company also announced Janet Liang will join as President of Oscar Health Insurance on February 24, 2025.